{"id":250087,"date":"2023-02-06T00:00:00","date_gmt":"2023-02-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0155-biopharma-hidradenitis-suppurativa-epidemiology-mature\/"},"modified":"2026-04-17T05:19:22","modified_gmt":"2026-04-17T05:19:22","slug":"epidim0155-biopharma-hidradenitis-suppurativa-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0155-biopharma-hidradenitis-suppurativa-epidemiology-mature-markets\/","title":{"rendered":"Hidradenitis Suppurativa &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of hidradenitis suppurativa (<abbr data-abbreviation-entity=\"10071\" title=\"hidradenitis suppurativa\">HS<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed incidence and prevalence of <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> for each country, as well as annualized case counts projected to the national population. Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How many people in each of the major mature pharmaceutical markets have been formally diagnosed with <abbr title=\"hidradenitis suppurativa\">HS<\/abbr>?<\/li>\n<li>How does the severity of <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> differ between newly diagnosed and existing prevalent <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> cases?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts five <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases.<\/li>\n<li>Diagnosed prevalent cases.<\/li>\n<li>Diagnosed incident cases by severity.<\/li>\n<li>Diagnosed prevalent cases by severity.<\/li>\n<li>Diagnosed prevalent cases by site of major lesions.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250087","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250087\/revisions"}],"predecessor-version":[{"id":281837,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250087\/revisions\/281837"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}